LAGOSTA S.A. announces that it has entered into a collaboration with the global science and technology company Merck for the distribution of LAGOSTA’s unique chitosan through their Life Science business’ industry-leading eCommerce platform. The compound can be used by pharma, biotech and the biomedical industry for R&D use only, in drug delivery applications, 3D bioprinting and medical devices.
Under the agreement, the Life Science business of Merck will employ its sales, marketing and eCommerce expertise, and leverage the strength of its relationships with the scientific community, to present and distribute LAGOSTA’s premium chitosan.
“This partnership clearly underlines and validates the uniqueness of our outstanding chitosan profile. Accessing such a premium product via Merck unlocks an unlimited potential of biomedical development opportunities for scientists around the world” said Christophe Maier, Founder and CEO at LAGOSTA S.A.
Through a farmed, sustainable production, LAGOSTA allows for high quality and consistent reproducibility chitosan, a biopolymer which we know is antimicrobial, biocompatible and biodegradable, unlocking potential for research in a number of areas, from implants to batteries.